UNSPSC 51431602: Atomoxetine

This classification denotes an antidepressant agent with the molecular formula C17H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ASW034S0B8, chemically known as benzenepropanamine, n-methyl-gamma-(2-methylphenoxy)-, (gammar)- but generally known as atomoxetine, which bears US NIH Compound Identifier 54841. Atomoxetine most often comes in base and hydrochloride forms. The term ATOMOXETINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3, 2002, List 48).

World Health Organization schedules atomoxetine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, ATOMOXETINE remains the US FDA Preferred Term for this commodity. Atomoxetine bears US NLM identifiers UMLS ID C0076823 and NCI Concept Code C74141. SMILES: CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2.

UNSPSC 51431602 Atomoxetine is a Commodity code covering specific pharmaceutical products procured by state and local health agencies, emergency medical services, and pharmacy benefit programs. State and local governments buy atomoxetine and related medications under this code as part of broader pharmaceutical supply contracts for emergency response, institutional health care delivery, and multi-state pharmacy cooperative purchasing programs. Recent solicitations show acquisition of both standalone emergency medications and inclusion within large multi-source generic pharmaceutical frameworks serving multiple jurisdictions and facility types.

Issuing bodies include city fire rescue departments, state health and human services commissions, and state-administered multistate cooperative purchasing alliances serving health care systems across participating states. The City of Tampa Fire Rescue, Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the mix of municipal emergency services, state health agencies, and cooperative purchasing vehicles active under this code. Geographic activity spans Texas, Minnesota, Florida, and Oregon, with MMCAP's multistate cooperative structure extending reach across participating jurisdictions. Representative recent opportunities include the City of Tampa Purchasing Department's sealed bid (26P00188) for Advanced Life Support Medications due April 8, 2026, with estimated contract value of $40,000 and a one-year term plus two optional renewals; MMCAP's RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, establishing two-year contracts effective July 1, 2026, and requiring vendors to maintain relationships with AmerisourceBergen, Cardinal Health, and Morris & Dickson wholesalers; and the Texas HHS Commission's RFI (HHS0017013) exploring direct-to-manufacturer prescription programs outside traditional PBM and GPO channels, posted April 3, 2026, to inform future formal procurement strategy. All solicitations require FDA compliance, cGMP certification, safety documentation, and expiration-date warranties extending six to nine months minimum from delivery.